NCT04400032View on ClinicalTrials.gov

Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 15, 2020

Primary Completion Date

April 22, 2021

Study Completion Date

April 22, 2021

Conditions
Acute Respiratory Distress SyndromeCovid19
Interventions
BIOLOGICAL

Mesenchymal Stromal Cells

The Mesenchymal Stromal Cells will be administered intravenously

Trial Locations (1)

K1H 8L6

The Ottawa Hospital, Ottawa

Sponsors

Collaborators (1)

Ontario Research Fund
All Listed Sponsors
collaborator

Stem Cell Network

OTHER

collaborator

Ontario Research Fund

OTHER

lead

Ottawa Hospital Research Institute

OTHER